(Total Views: 401)
Posted On: 03/15/2020 8:07:08 AM
Post# of 149265
Re: biloxiblues #21608
In the article "Disabling CCR5 Could Be Key to a Cure—but at What Cost" they make a case against CCR5 inhibition. With any method that involves eliminating or complete blockage of CCR5 they may have a point. In an individual exhibiting CCR5, eliminating it results in the immune system using secondary receptors with less binding affinity.
Their citing of the white paper "Deviations from Hardy Weinberg Equilibrium at CCR5-Δ32 in Large Sequencing Data Sets?" is a bit off since the contributing data is not trustworthy and states that at the top of the paper.
https://www.biorxiv.org/content/10.1101/768390v2
But then we come to leronlimab. Leronlimab establishes only a partial blockade of the CCR5 receptor and still allows immune system function. That the developers of leronlimab chose this particular molecular structure was quite fortuitous.
Their citing of the white paper "Deviations from Hardy Weinberg Equilibrium at CCR5-Δ32 in Large Sequencing Data Sets?" is a bit off since the contributing data is not trustworthy and states that at the top of the paper.
https://www.biorxiv.org/content/10.1101/768390v2
But then we come to leronlimab. Leronlimab establishes only a partial blockade of the CCR5 receptor and still allows immune system function. That the developers of leronlimab chose this particular molecular structure was quite fortuitous.
(4)
(0)Scroll down for more posts ▼
